WCG Announces the Formation of WCG IRB and Launch of WCG IRB Connexus
WCG has announced the unification of its five IRBs—Western IRB (WIRB), Copernicus Group IRB (CGIRB), Midlands IRB (MLIRB), New England IRB (NEIRB), and Aspire IRB—into the single WCG IRB brand. Since 2012, the organization has assembled and integrated an array of IRBs, now synthesized into a single IRB. WCG IRB clients will experience a singular, unified process and submission platform.
This transformation includes the launch of a new technology, WCG IRB Connexus, which supports their clients’ ethical review submissions and management.
“By deploying adaptive technology, the new WCG IRB Connexus supports our commitment to continuous improvement of our processes by raising the bar on transparency and compliance,” said David Forster, WCG’s Chief Compliance Officer. “And that’s our goal—to improve the submission process, eliminate and reduce errors."
Details of these changes are being announced this week through the WCG IRB website.
Read more in the full release, here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
